Nisa Investment Advisors LLC Has $6.68 Million Stock Position in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Nisa Investment Advisors LLC lifted its position in shares of Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 1.2% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 63,099 shares of the medical equipment provider’s stock after purchasing an additional 729 shares during the quarter. Nisa Investment Advisors LLC’s holdings in Zimmer Biomet were worth $6,680,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other large investors have also modified their holdings of ZBH. Roberts Wealth Advisors LLC acquired a new position in shares of Zimmer Biomet in the 4th quarter valued at $1,954,000. Lmcg Investments LLC lifted its stake in Zimmer Biomet by 20.4% during the fourth quarter. Lmcg Investments LLC now owns 55,949 shares of the medical equipment provider’s stock worth $5,910,000 after purchasing an additional 9,484 shares during the period. Ballentine Partners LLC boosted its holdings in Zimmer Biomet by 18.6% during the fourth quarter. Ballentine Partners LLC now owns 4,571 shares of the medical equipment provider’s stock valued at $483,000 after purchasing an additional 716 shares in the last quarter. Culbertson A N & Co. Inc. grew its stake in shares of Zimmer Biomet by 3.2% in the 4th quarter. Culbertson A N & Co. Inc. now owns 5,998 shares of the medical equipment provider’s stock valued at $634,000 after purchasing an additional 185 shares during the period. Finally, MassMutual Private Wealth & Trust FSB raised its holdings in shares of Zimmer Biomet by 42.9% in the 4th quarter. MassMutual Private Wealth & Trust FSB now owns 27,270 shares of the medical equipment provider’s stock worth $2,881,000 after buying an additional 8,191 shares in the last quarter. 88.89% of the stock is currently owned by institutional investors and hedge funds.

Wall Street Analyst Weigh In

A number of analysts have weighed in on the company. Wells Fargo & Company upped their price target on Zimmer Biomet from $110.00 to $117.00 and gave the company an “equal weight” rating in a research report on Thursday, October 31st. Evercore ISI dropped their target price on shares of Zimmer Biomet from $113.00 to $110.00 and set an “in-line” rating for the company in a research report on Tuesday, October 1st. Raymond James reduced their price target on shares of Zimmer Biomet from $128.00 to $123.00 and set an “outperform” rating on the stock in a research report on Monday, October 14th. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the stock from $125.00 to $128.00 in a report on Tuesday, December 17th. Finally, Stifel Nicolaus boosted their target price on Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a report on Thursday. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and nine have assigned a buy rating to the company. According to MarketBeat, Zimmer Biomet has an average rating of “Hold” and a consensus price target of $124.11.

Zimmer Biomet Price Performance

NYSE:ZBH opened at $110.78 on Friday. The company has a current ratio of 1.36, a quick ratio of 0.70 and a debt-to-equity ratio of 0.38. The firm has a fifty day simple moving average of $107.89 and a 200 day simple moving average of $108.09. Zimmer Biomet Holdings, Inc. has a 1-year low of $100.67 and a 1-year high of $133.90. The stock has a market capitalization of $22.05 billion, a PE ratio of 21.06, a P/E/G ratio of 1.88 and a beta of 1.02.

Zimmer Biomet (NYSE:ZBH) last issued its earnings results on Wednesday, October 30th. The medical equipment provider reported $1.74 earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of $1.74. Zimmer Biomet had a net margin of 14.27% and a return on equity of 12.95%. The company had revenue of $1.82 billion for the quarter, compared to analysts’ expectations of $1.80 billion. During the same period in the prior year, the firm earned $1.65 EPS. Zimmer Biomet’s quarterly revenue was up 4.1% compared to the same quarter last year. On average, research analysts expect that Zimmer Biomet Holdings, Inc. will post 7.99 EPS for the current fiscal year.

Zimmer Biomet Announces Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, January 31st. Investors of record on Monday, December 30th will be paid a $0.24 dividend. This represents a $0.96 dividend on an annualized basis and a yield of 0.87%. The ex-dividend date of this dividend is Monday, December 30th. Zimmer Biomet’s dividend payout ratio (DPR) is presently 18.25%.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.